logo

For the Inventor, By the Inventor

Wallingford, PA, United States of America

Kang Sun

This inventor holds 7 USPTO granted patents and 6 published patent applications. Top assignee: Incyte Corporation. Active years: 2022-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kang Sun. Retrieved from https://idiyas.com/inventor/kang-sun-3pt6ou15

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 7 

% Patents Active = 85.7

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:

goldMedal7 out of 687 
 
Incyte Corporation
 patents

Years Active: 2022-2026

Loading Chart...
7 patents (USPTO):Explore Patents
1. 12589096 - Ruxolitinib formulation for reduction of itch in atopic dermatitis (2026-03-31),
2. 12396993 - Ruxolitinib formulation for reduction of itch in atopic dermatitis (2025-08-26),
3. 12233067 - Topical treatment of vitiligo by a JAK inhibitor (2025-02-25),
4. 11602536 - Topical treatment of vitiligo by a JAK inhibitor (2023-03-14),
5. 11590138 - Topical treatment of vitiligo by a jak inhibitor (2023-02-28),
6. 11590137 - Ruxolitinib formulation for reduction of itch in atopic dermatitis (2023-02-28),
7. 11510923 - Ruxolitinib formulation for reduction of itch in atopic dermatitis (2022-11-29),

Title: The Innovations of Kang Sun

Introduction

Kang Sun is a notable inventor based in Wallingford, PA (US). He has made significant contributions to the field of dermatology, particularly in the treatment of atopic dermatitis. With a total of 7 patents to his name, his work has had a meaningful impact on patient care.

Latest Patents

One of Kang Sun's latest patents involves a ruxolitinib formulation aimed at reducing itch in patients with atopic dermatitis. This disclosure outlines methods for alleviating itch and treating patients by administering a topical cream containing either 0.75% or 1.5% ruxolitinib two times per day. This innovative approach represents a significant advancement in the management of this chronic skin condition.

Career Highlights

Kang Sun is currently employed at Incyte Corporation, where he continues to develop groundbreaking treatments. His expertise in dermatological formulations has positioned him as a key player in the pharmaceutical industry. His dedication to improving patient outcomes is evident in his research and patent filings.

Collaborations

Kang Sun has collaborated with several esteemed colleagues, including Jim Lee and Michael D Howell. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.

Conclusion

Kang Sun's contributions to the field of dermatology through his patents and collaborations highlight his commitment to advancing medical science. His work continues to pave the way for improved treatments for patients suffering from atopic dermatitis.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…